Check back often to find the latest news on AgeneBio and our pipeline of multiple candidates.
AgeneBio, Inc. panel participation at American College of Neuropsychopharmacology meeting (ACNP)
Bridging the Gap From Research Discovery to a Bonafide Neurotherapeutic: Sponsored by NIH Blueprint Neurotherapeutic Program
Sharon Rosenzweig-Lipson, AgeneBio VP of R&D. presents at Clinical Trials in Alzheimer’s Disease conference (CTAD)
Founder & CEO Dr. Michela Gallagher Featured in Alzheimer’s Drug Discovery Foundation Video
Learn more about our important work in this video.
AgeneBio using over $3M in new funding to further develop Alzheimer’s drug
The Baltimore Business Journal covered our funding for Alzheimer's drug development.
AgeneBio Announces Additional Funding to Advance Novel GABA-A Therapeutic Program to Address Alzheimer’s and Other CNS Conditions
AgeneBio today announced it has received significant additional resources to accelerate the development of their GABA-A a5 Positive Allosteric Modulation (PAM), a novel approach to mild cognitive impairment (MCI) due to Alzheimer's Disease (AD) that targets hippocampal overactivity that leads to degeneration and cognitive decline in patients with MCI due to AD, autism and schizophrenia.
T.J. Oshie and Dr. Michela Gallagher Honored at Ninth Annual Great Ladies Luncheon
Dr. Michela Gallagher, founder and CEO of AgeneBio, Inc. and professor at Johns Hopkins University, was honored at the luncheon for her work advancing treatments for Alzheimer's disease. Dr. Gallagher received the inaugural Estelle Gelman Award for Innovation in Drug Discovery for her groundbreaking research that holds the potential to yield the first drug to slow the progression of symptoms associated with mild cognitive impairment due to Alzheimer's disease.
AgeneBio Believes a Switch in Research Strategy Can Make Alzheimer’s Preventable
Michela Gallagher, CEO of AgeneBio, and her staff have given themselves a big challenge – to develop the first and only therapeutic targeting brain network imbalance and potentially the first therapeutic to slow progression to and delay the onset of Alzheimer’s…
AgeneBio Announces First Patient Enrollment in the Phase 3 Clinical Trial to Evaluate AGB101 to Treat Amnestic Mild Cognitive Impairment Due to Alzheimer’s Disease
AGB101 is the first investigational therapeutic that targets the reduction of hippocampal overactivity. The study evaluates both Primary and Secondary Endpoints to measure cognitive and functional efficacy. Secondary imaging endpoints will include measures of neurodegeneration. BALTIMORE, MD (January 17, 2019)…
AgeneBio Announces Two NIH Grant Awards to Advance its Therapeutic Pipeline to Combat Progression of Alzheimer’s Disease
– NIH awards an expected $16 million to support Phase 3 pivotal clinical trial of AGB-101, a once-a-day treatment to slow progression in Mild Cognitive Impairment due to Alzheimer’s disease. – NIH awards follow on funding from the Blueprint Neurotherapeutics…
